General Information of Drug (ID: DM6YAGE)

Drug Name
RWJ-67657 Drug Info
Synonyms
215303-72-3; RWJ-67657; RWJ 67657; RWJ67657; 4-[4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1-ol; CHEMBL190333; 4-(4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl)but-3-yn-1-ol; 4-(4-Fluorophenyl)-2-(4-hydroxy-1-butynyl)-1-(3-Phenylpropyl)-5-(4-Pyridyl)imidazole; 4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridyl)imidazol-2-yl]but-3-yn-1-ol; 4-(4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl)-3-butyn-1-ol
Indication
Disease Entry ICD 11 Status REF
Arthritis FA20 Phase 1 [1]
Therapeutic Class
Analgesics
Cross-matching ID
PubChem CID
3008319
CAS Number
CAS 215303-72-3
TTD Drug ID
DM6YAGE

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin G/H synthase 2 (COX-2) TTVKILB PGH2_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Arthritis
ICD Disease Classification FA20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Prostaglandin G/H synthase 2 (COX-2) DTT PTGS2 7.93E-04 -0.29 -0.34
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J Pharmacol Exp Ther. 1999 Nov;291(2):680-7.
2 Monocyte intracellular cytokine production during human endotoxaemia with or without a second in vitro LPS challenge: effect of RWJ-67657, a p38 MAP-kinase inhibitor, on LPS-hyporesponsiveness. Clin Exp Immunol. 2002 Feb;127(2):337-43.